Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGAV | P06756 | 16/20 | 0.57 |
| ▸ | ITGB3 | P05106 | 14/20 | 0.57 |
| ▸ | CXCR4 | P61073 | 4/20 | 0.56 |
| ▸ | ITGB6 | P18564 | 7/20 | 0.55 |
| ▸ | ITGB5 | P18084 | 6/20 | 0.53 |
| ▸ | ITGB8 | P26012 | 5/20 | 0.53 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23542430 | 0.93 | ITGAV (0.61) | ITGAVITGB3CXCR4ITGB6ITGB5 | |
| SCHEMBL5251099 | 0.91 | ITGAV (0.66) | ITGAVITGB3ITGB6ITGB5ITGB8 | |
| SCHEMBL6424829 | 0.90 | ITGAV (0.65) | ITGAVITGB3ITGB6ITGB5ITGB8 | |
| SCHEMBL6421229 | 0.90 | ITGAV (0.65) | ITGAVITGB3ITGB6ITGB5ITGB8 | |
| SCHEMBL5252354 | 0.88 | ITGAV (0.53) | ITGAVITGB3CXCR4ITGB6ITGB5 | |
| SCHEMBL15062815 | 0.87 | CXCR4 (0.53) | ITGAVITGB3CXCR4ITGB6ITGB5 | |
| Hydrochloric Acid SCHEMBL3103027 | 0.86 | CXCR4 (0.52) | ITGAVITGB3CXCR4ITGB6ITGB5 | |
| SCHEMBL760607 | 0.84 | ITGB3 (0.69) | ITGAVITGB3ITGB6ITGB5ITGB8 | |
| SCHEMBL25638062 | 0.82 | ITGAV (0.60) | ITGAVITGB3ITGB6ITGB5ITGB8 | |
| SCHEMBL13007683 | 0.82 | ITGAV (0.63) | ITGAVITGB3ITGB6ITGB5ITGB8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220144853-A1 | IMIDAZOLINE DERIVATIVES AS CXCR4 MODULATORS | Université de Paris (FR) | 2022-05-12 | — | — | US | disclosed |
| US-20220144853-A1 | IMIDAZOLINE DERIVATIVES AS CXCR4 MODULATORS | Université de Paris (FR) | 2022-05-12 | — | — | US | disclosed |
| EP-3947394-A1 | IMIDAZOLINE DERIVATIVES AS CXCR4 MODULATORS | Université de Paris (FR) | 2022-02-09 | — | — | EP | disclosed |
| CN-113939521-A | Imidazoline derivatives as CXCR4 modulators | 巴黎大学 | 2022-01-14 | — | — | CN | disclosed |
| WO-2020201096-A1 | IMIDAZOLINE DERIVATIVES AS CXCR4 MODULATORS | Université de Paris (FR) | 2020-10-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220144853-A1 | IMIDAZOLINE DERIVATIVES AS CXCR4 MODULATORS | CXCR4, CXCL12, CXCR1 | ITGAV 934/4885ITGB3 887/4885CXCR4 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.